

**Amexdrug Corporation**

(Exact name of registrant as specified in its charter)

NEVADA

90-0017017

(State

or other jurisdiction of  
or organization)

(I.R.S. Employer identification No.) incorporation

6465 Corvette Street

Commerce, California 90040

(Address of principal executive offices) (Zip code)

Registrant's telephone number: (323) 725-3100

**IR Contact**

Jack Amin  
6465 Corvette Street  
Commerce, CA 90040  
(323) 725-3100

Trading Symbol: AXRX

CUSIP: 031139207 Par

Value: \$0.001

Total shares authorized: 1,000,000,000 as of December 31, 2018

Total shares outstanding: 169,409,620 as of December 31, 2018

**Transfer Agent**

Pacific Stock Transfer  
6725 Via Austi Pkwy, Ste 300  
Las Vegas, Nevada 89119  
Tel: 702-361-3033

The Transfer Agent is registered under the Exchange Act.

**Issuance History**

In the past two years, the Company has not conducted any private placements of equity securities or convertible debt financing.

## TABLE OF CONTENTS

	<u>Page</u>
<b>Item 3.</b> Financial Statements.....	3
Condensed Consolidated Balance Sheets.....	4-5
Condensed Consolidated Statements of Income.....	6-7
Notes to Condensed Consolidated Financial Statements .....	8-9
<b>Item 4.</b> Business Segment Information .....	10-11
<b>Item 5.</b> Identification of Directors and Executive Officers.....	12
<b>Item 6.</b> Legal Proceedings .....	13
<b>Item 7.</b> Certifications.....	14

### **Item 3. Financial Statements.**

The consolidated balance sheets of Amexdrug Corporation, a Nevada corporation, and subsidiaries as of March 31, 2024, the related condensed consolidated statements of income for the three months ended March 31, 2024. The condensed consolidated financial statements have been prepared by Amexdrug's management.

The accompanying consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to present fairly the results of operations and financial position of Amexdrug Corporation consolidated with BioRx Pharmaceuticals, Inc., Allied Med, Inc., and Dermagen, Inc., its wholly owned subsidiaries, and all such adjustments are of a normal recurring nature. The names "Amexdrug", "we", "our" and "us" used in this report refer to Amexdrug Corporation.

**Financial Statements**

**of  
AMEXDRUG  
For the Period Ended March 31, 2024**

See Accompanying Accountant's Compilation Report

**AMEXDRUG**  
**Balance Sheet**  
**March 31, 2024**

**ASSETS**

**Current Assets**

A-SC Checking 2551	\$	12,555.75
A-SC Checking 5240		151.17
B-SC Checking 2577		56,708.10
B-SC Checking 5232		65,686.25
Bank of Santa Clarita 2585		6,142.00
Bank of Santa Clarita 7220		178.07
Petty Cash		450.00
Other Deposits		13,362.00
Accounts Receivable		518,661.12
Advance Officer		7,413.34
Investment Dermagen		1,248,267.50
Iner Co Rec Allied		18,893.05
Book of Customers		18,259.00
Goodwill		17,765.00
Inventory		498,340.00
Fed Deposit		10,000.00
State Deposit		4,000.00
Investment Scottrade		<u>9,643.62</u>

**Total Current Assets** \$ 2,506,475.97

**Fixed Assets**

Leasehold Improvements	15,700.00
Property & Equipment	255,329.33
Deferred Tax Asset	6,300.00
Security Deposits	17,000.00
Accumulated Depreciation	<u>(271,031.00)</u>

**Total Fixed Assets** 23,298.33

**Other Assets**

Trademark	1,650.00
Website Design	3,325.00
Amort Book of TM & Website	<u>(23,234.00)</u>

**Total Other Assets** (18,259.00)

**Total Assets** \$ 2,511,515.30

**AMEXDRUG**  
**Balance Sheet**  
**March 31, 2024**

**LIABILITIES AND EQUITY**

**Current Liabilities**

Accounts Payable - Trade	\$	241,860.38
Accrued Payroll Taxes		8,247.74
sales tax payable		<u>3,690.00</u>

**Total Current Liabilities** \$ 253,798.12

**Long Term Liabilities**

Bank of Santa Clarita		<u>481,192.89</u>
-----------------------	--	-------------------

**Total Long Term Liabilities** 481,192.89

**Equity**

Capital Stock		169,410.00
Retained Earnings		1,583,642.07
Current Income (Loss)		<u>23,472.22</u>

**Total Equity** 1,776,524.29

**Total Liabilities & Equity** \$ 2,511,515.30

**AMEXDRUG**  
**Income Statement**  
**For the Period Ended March 31, 2024**

	3 Months Ended Mar. 31, 2024	Pct	3 Months Ended Mar. 31, 2024	Pct
<b>Revenue</b>				
Sales	\$ <u>956,172.87</u>	<u>100.00</u>	\$ <u>956,172.87</u>	<u>100.00</u>
<b>Total Revenue</b>	956,172.87	100.00	956,172.87	100.00
<b>Cost of Sales</b>				
Purchases	343,138.77	35.89	343,138.77	35.89
Shipping	132,207.23	13.83	132,207.23	13.83
Packaging	6,005.48	0.63	6,005.48	0.63
ATS Payments	<u>11,481.72</u>	<u>1.20</u>	<u>11,481.72</u>	<u>1.20</u>
<b>Total Cost of Sales</b>	<u>492,833.20</u>	<u>51.54</u>	<u>492,833.20</u>	<u>51.54</u>
<b>Gross Profit</b>	463,339.67	48.46	463,339.67	48.46
<b>Operating Expenses</b>				
Advertising & Promotion	1,198.50	0.13	1,198.50	0.13
Auto/Truck Expenses	2,281.10	0.24	2,281.10	0.24
Auto Lease	2,387.82	0.25	2,387.82	0.25
Bank Service Charges	2,332.79	0.24	2,332.79	0.24
CC Bank Discounts	15,449.32	1.62	15,449.32	1.62
Bad Debt Expense	185,287.00	19.38	185,287.00	19.38
Dues & Subscriptions	1,067.82	0.11	1,067.82	0.11
Interest	11,481.71	1.20	11,481.71	1.20
Licenses & Fees	241.41	0.03	241.41	0.03
Legal	879.00	0.09	879.00	0.09
Insurance	16,461.75	1.72	16,461.75	1.72
Maintenance & Repairs	1,265.00	0.13	1,265.00	0.13
Office Supplies	1,195.19	0.12	1,195.19	0.12
Outside Services	43,067.50	4.50	43,067.50	4.50
Postage	8,000.00	0.84	8,000.00	0.84
Rent - Building	67,777.92	7.09	67,777.92	7.09
Rent - Equipment	96.00	0.01	96.00	0.01
Security	1,323.43	0.14	1,323.43	0.14
skype exp	291.61	0.03	291.61	0.03
Telephone	2,708.18	0.28	2,708.18	0.28
Trash	507.36	0.05	507.36	0.05
Supplies	1,057.63	0.11	1,057.63	0.11
Utilities	1,356.09	0.14	1,356.09	0.14
Travel	6,482.37	0.68	6,482.37	0.68
Miscellaneous	628.57	0.07	628.57	0.07
Salaries & Commissions	59,848.00	6.26	59,848.00	6.26
Taxes - Payroll	<u>5,194.38</u>	<u>0.54</u>	<u>5,194.38</u>	<u>0.54</u>
<b>Total Operating Expenses</b>	<u>439,867.45</u>	<u>46.00</u>	<u>439,867.45</u>	<u>46.00</u>
<b>Operating Income</b>	<u>23,472.22</u>	<u>2.45</u>	<u>23,472.22</u>	<u>2.45</u>

See Accompanying Accountant's Compilation Report

	3 Months Ended Mar. 31, 2024	Pct	3 Months Ended Mar. 31, 2024	Pct
<b>Total Other Income</b>	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>	<u>0.00</u>
<b>Net Income (Loss)</b>	\$ <u><u>23,472.22</u></u>	<u>2.45</u>	\$ <u><u>23,472.22</u></u>	<u>2.45</u>

See Accompanying Accountant's Compilation Report

AMEXDRUG CORPORATION AND SUBSIDIARIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL  
STATEMENTS – (UNAUDITED)  
March 31, 2024

1. Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending March 31, 2024. For further information refer to the financial statements and footnotes thereto included in the Company's annual filing for the year ended December 31, 2018.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

This summary of significant accounting policies of Amexdrug Corporation is presented to assist in understanding the Company's financial statements. The financial statements and notes are representations of the Company's management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.

Revenue Recognition

The Company generates revenues from the manufacture and resale of pharmaceuticals, over-the-counter products, health and beauty care products and nutritional supplements. The Company accounts for these revenues at the time of shipment to the customer. An allowance for sales returns is provided for products sold on a cash-on-delivery basis that are not accepted or paid for by the customer.

Cash and Cash Equivalent

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

Investments

Certificate of Deposits with banking institutions are short-term investments with initial maturities of more than 90 days. The carrying amount of these investments is a reasonable estimate of fair value due to their short-term nature.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. Significant estimates made in preparing these financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, and the fair value of stock options. Actual results could differ from those estimates.

Fair Value of Financial Instruments

Fair Value of Financial Instruments, requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of March 31, 2024, the amounts reported for cash, accounts receivable, accounts payable, accrued interest and other expenses, and notes payable approximate the fair value because of their short maturities.

Basic Income per Share Calculations

Basic income per share is computed by dividing net income by the weighted-average number of common shares outstanding. As of March 31, 2024, the Company did not have any potentially issuable common shares outstanding; accordingly, diluted income per share is not applicable to the Company and is not presented.

Income Taxes

The Company uses the liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to financial statements carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. The measurement of deferred tax assets and liabilities is based on provisions of applicable tax law. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance based on the amount of tax benefits that, based on available evidence, is not expected to be realized.

AMEXDRUG CORPORATION AND SUBSIDIARIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL  
STATEMENTS - (UNAUDITED)  
March 31, 2024

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

Accounts Receivable

An allowance for uncollectible accounts receivable is established by charges to operations for amounts required to maintain an adequate allowance, in management's judgment, to cover anticipated losses from customer accounts and sales returns. Such accounts are charged to the allowance when collection appears doubtful. Any subsequent recoveries are credited to the allowance account.

Inventory

Inventory includes purchased products for resale and raw materials and supplies necessary to manufacture pharmaceuticals, medical devices, and health and beauty products and is stated at the lower of cost (using the first-in, first-out method) or net realizable value. Provisions, when required, are made to reduce excess and expired inventory to its estimated net realizable value. Although competitive pressures and pharmaceutical advancements expose the Company to the risk that estimates of the net realizable value could change in the near term, the Company's agreements with most vendors provide for the right of return of outdated or expired inventory. The Company is exposed to other ownership related risks associated with inventory.

3. BUSINESS SEGMENT INFORMATION

The Company has operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products.

4. SUBSEQUENT EVENTS

Management has evaluated subsequent events according to the requirements of ASC TOPIC 855, and has determined there are no subsequent events to be reported.

#### **Item 4. BUSINESS SEGMENT INFORMATION**

The Company has operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products.

Amexdrug Corporation is located at 6465 Corvette Street, Commerce, California 90040. Its phone number is (323) 725-3100. Its fax number is (323)725-3133. Its website is [www.amexdrug.com](http://www.amexdrug.com). Shares of Amexdrug common stock are traded on the OTC Bulletin Board under the symbol AXRX.OB. The President of Amexdrug has had experience working in the pharmaceutical industry for the past 30 years.

Amexdrug Corporation, through its wholly-owned subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care, Inc., is a pharmaceutical and cosmeceutical company specializing in the research and development, manufacturing and distribution of pharmaceutical drugs, cosmetics and distribution of prescription and over-the-counter drugs, private manufacturing and labeling and a quality control laboratory. At Amexdrug Corporation, it is our anticipation to give our clientele the opportunity to purchase cost effective products while attempting to maximize the return of investments to our shareholders.

Amexdrug Corporation distributes its products through its subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care, Inc. primarily to independent pharmacies and secondarily to small-sized pharmacy chains, alternative care facilities and other wholesalers and retailers in the state of California.

BioRx Pharmaceuticals, Inc. is a proud member of the National Association of Chain Drug Stores (NACDS). BioRx Pharmaceuticals, Inc. has developed fourteen unique innovative products in the industry under the name Sponix.

Our team of professionals fully pledges the effectiveness of our distinct products.

At this time, we have certain distribution channels with suppliers and customers whom we know and trust, such as Amazon, and hundreds of independent pharmacies.

References in this report to "we," "our," "us," the "company" and "Amexdrug" refer to Amexdrug Corporation and also to our subsidiaries, BioRx Pharmaceuticals, Inc., Allied Med, Inc., Dermagen, Inc. and Royal Health Care.

#### **BioRx Pharmaceuticals**

BioRx Pharmaceuticals, Inc. as a Nevada corporation which sells pharmacy and laboratory supplies nationwide. BioRx Pharmaceuticals, Inc. is also committed to offer skin care and over the counter (OTC) products that are recommended with trust and faith by physicians, primarily podiatrists and dermatologists. The focus and mission of BioRx Pharmaceuticals, Inc. is to create, develop and manufacture products to help ease pain and restore and maintain the overall well-being of our customers. We strive for high performance and quality. Our commitment is to offer natural and OTC products that are recommended with confidence by doctors and pharmacists and that the customer can use with pleasure. Our compliance program is diligently followed through the Company. BioRx Pharmaceuticals, Inc. maintains high ethics for animal welfare and our products are never tested on animals. All products are made in the USA.

A total of fourteen innovative health and wellness products have been manufactured for sale by BioRx Pharmaceuticals, Inc. These over-the-counter and natural products are effective for treatment of fungus, arthritis, sunburn protection and for healthy feet and nails. BioRx Pharmaceuticals is planning to sell these products to national chain drugstores, sport chain stores, natural food markets and other mass markets. These products are being marketed under the name of Sponix, and are being sold under the name of BioRx Pharmaceuticals.

We have added the BioRx Beauty line to sell to beauty supply stores and professional salons. In addition we are in process of selling electronic consumer products to our customers and on line markets, such as Amazon and Ebay. We believe this new segment will potentially be a great revenue for Amexdrug Corporation's bottom line.

#### **Allied Med, Inc.**

Allied Med, Inc operates in the pharmaceutical wholesale business of selling a full line of brand name and generic pharmaceutical products, over-the-counter (OTC) drug and non-drug products and health and beauty products to independent and chain pharmacies, alternative care facilities and other wholesalers. At Allied Med our sincere interest is our customers' needs. Our competitive discount pricing allows our customers an advantage.

Amexdrug assumed the operations of Allied Med, and Amexdrug has been building on the wholesale pharmaceutical operations of Allied Med.

#### **Dermagen, Inc.**

Dermagen, Inc. is a growing manufacturing company specializing in the manufacturing and distribution of certain pharmaceuticals and health and beauty products. Dermagen, Inc. has a U.S.-FDA registered and state FDA approved manufacturing facility licensed to develop high margin skin and novel health and beauty products for niche markets. Dermagen's competitive advantage is in its excellent product research and development.

#### **Item 4. BUSINESS SEGMENT INFORMATION (Continued)**

##### **Royal Health Care Company**

Royal Health Care Company is a health and beauty company which has sold specially manufactured facial and body creams, arthritic pain relief medications and an exclusive patented hair care product to pharmacies, beauty salons, beauty supply stores and other fine shops. Royal Health Care Company uses the highest quality ingredients for the finest quality products. Each product has been formulated with the essential ingredients and plant extracts to achieve optimum potential and quality. Royal Health Care Company products are manufactured by Dermagen, Inc. in an FDA approved manufacturing facility.

Royal Health Care, Inc. manufactures and sells health and beauty products.

##### **Lease Agreements**

The Company's principal executive offices and its warehouse and distribution operations moved to 6465 Corvette Street, Commerce California in August 2017. The Company leases 22,000 square feet at this location. Approximately 2,500 square feet of the premises is used for executive offices, and the balance of the premises is used for warehouse and distribution operations. The lease was entered into on April 29, 2016. The term of the lease is twenty-five (25) years, commencing May 1, 2016 and ending April 30, 2041.

The Company's Dermagen, Inc. manufacturing operations are currently located at 2500 East Fender Avenue, Units I & J, Fullerton, California, which is leased under one lease agreement. The lease goes through February 28, 2019. The Company leases approximately 3,520 square feet at a rental rate of \$2,605 per month. Payment of the lease has been personally guaranteed by Jack Amin. The Company believes this space will be sufficient for at least the next twelve months.

The Company believes that the various facilities covered by the leases described above will be sufficient for at least the next twelve months.

##### **Business Segments**

Amexdrug has operations in two segments of its business, namely: Distribution and Health and Beauty Products. Distribution consists of the wholesale pharmaceutical distribution and resale of brand and generic pharmaceutical products, over-the-counter drugs and non-drug products and health and beauty products. Health and Beauty Products consist of the manufacture and distribution of primarily health and beauty products. Manufacturing includes expertise in research and development for health care industry products, including pharmacy supplies.

**Item 5. Identification of directors and executive officers**

<u>Name</u>	<u>Title</u>	<u>Number of shares Beneficially Owned</u>	<u>Percent of Class</u>
Jack Amin 6465 Corvette Street Commerce, CA 90040	President, Secretary, Treasurer and Director	155,184,040	91.7%
Rodney S. Baron, MD	Director	0	0.0%
Behrooz Meimand	Director	0	0.0%

**Item 6. Legal Proceedings**

To the best of Amextrug's knowledge, no governmental authority is contemplating the filing of any material legal proceeding against the Company or its officers and directors.

Legal Counsel

Robert Wilkinson  
136 E. South Temple #2400  
Salt Lake City, UT 84111  
(801) 533-9645

Anthony E. Bell  
515 S. Flower Street, 36<sup>th</sup> Floor  
Los Angeles, CA 90071  
(213) 973-1288

Independent Accountant

Haynie & Company  
50 West Broadway, Suite 600  
Salt Lake City, UT 84101  
(801) 532-7800

Accountant

Arturo L. Filippa  
The Filippa Corporation  
1300 N. Potrero Grande Dr Suite A  
Rosemead, CA, 91770

**Certifications of Chief Executive Officer and Chief Financial Officer**

I, Jack Amin, certify that:

1. I have reviewed this quarterly report disclosure of Amexdrug Corporation;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: March 31, 2024

/s/ Jack Amin  
Jack Amin, Chief Financial Officer